Evidence map›Paper›PMID 16192645›Full record

ArticleThe American journal of pathology2005

NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis.

Wei Shen, Yong Li, Ying Tang, James Cummins, Johnny Huard

Registry-linked trialOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in The American journal of pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05637216 (A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients), which is not on this map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05637216 phase2active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

TypeinterventionalSponsorShaw Cancer CenterRan2023 to 2027Enrolled43ConditionsRadiation Induced FibrosisArmsLosartan 25 milligram capsule, Placebo
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 167 citations in OpenAlex.

  1. Effect of a cyclooxygenase-2 inhibitor on postexercise muscle protein synthesis in humans.American journal of physiology. Endocrinology and metabolism · 2010
    Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Actovegin® reduces PMA-induced inflammation on human cells.European journal of applied physiology · 2020
    Article
  14. Article
  15. Article
  16. Fibrosis following Acute Skeletal Muscle Injury: Mitigation and Reversal Potential in the Clinic.Journal of sports medicine (Hindawi Publishing Corporation) · 2020
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Wei ShenDepartments of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Yong Li
Ying Tang
James Cummins
Johnny Huard
University of Pittsburgh · USChildren's Hospital of Pittsburgh · US

Funding

STEM CELL BIOLOGY AND THERAPEUTICS CENTERC06RR014489 · NCRR · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · PI PERLMUTTER, DAVID H · 2001 to 2001
$1.3M
IMPROVING MUSCLE HEALING THROUGH PREVENTION OF FIBROSISR01AR047973 · NIAMS · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · PI HUARD, JOHNNY · 2001 to 2004
$1.1M
NCRR NIH HHS C06 RR014489NCRR NIH HHS C06 RR 14489NIAMS NIH HHS 1 R01 AR 47973NIAMS NIH HHS R01 AR047973
6 · The paper itself

Abstract

Nonsteroidal anti-inflammatory drugs are often prescribed after muscle injury. However, the effect of nonsteroidal anti-inflammatory drugs on muscle healing remains primarily controversial. To further examine the validity of using these drugs after muscle injury, we investigated the working mechanism of NS-398, a cyclooxygenase-2-specific inhibitor. In vitro experiments showed that NS-398 inhibited the proliferation and maturation of differentiated myogenic precursor cells, suggesting a detrimental effect on skeletal muscle healing. Using a mouse laceration model, we analyzed the in vivo effect of NS-398 on skeletal muscle healing at time points up to 4 weeks after injury. The in vivo results revealed delayed muscle regeneration at early time points after injury in the NS-398-treated mice. Compared to controls, lacerated muscles treated with NS-398 expressed higher levels of transforming growth factor-beta1, which corresponded with increased fibrosis. In addition, transforming growth factor-beta1 co-localized with myostatin, a negative regulator of skeletal muscle growth. We also found reduced neutrophil and macrophage infiltration in treated muscles, indicating that the delayed skeletal muscle healing observed after NS-398 treatment could be influenced by the anti-inflammatory effect of NS-398. Our findings suggest that the use of cyclooxygenase-2-specific inhibitors to treat skeletal muscle injuries warrants caution because they may interfere with muscle healing.

Indexed as

AnimalsAntibodies, MonoclonalBlotting, WesternCell Culture TechniquesCell DifferentiationCell ExtractsCell ProliferationCells, CulturedCollagenCyclooxygenase 2 InhibitorsDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayFemaleFibrosisFlow CytometryFluoresceinAntibodies, MonoclonalCell ExtractsCollagenCyclooxygenase 2 InhibitorsDAPIFluoresceinFluorescein-5-isothiocyanateFluorescent DyesIndolesMstn protein, mouseMyostatinN-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamideNitrobenzenesSulfonamidesTgfb1 protein, mouseTransforming Growth Factor betaTransforming Growth Factor beta1

Identifiers

PMID16192645
PMCPMC1603662
OpenAlexW2007293837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.